

12<sup>th</sup> August, 2025

To,

**The Corporate Relationship Department  
BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai 400 001.  
**Scrip Code: 539523**

**National Stock Exchange of India  
Limited**  
Exchange Plaza,  
Bandra Kurla Complex,  
Bandra East,  
Mumbai 400 051.  
**Scrip Symbol: ALKEM**

**Sub: Outcome of the Board Meeting held on 12<sup>th</sup> August, 2025**

Dear Sir(s)/ Madam,

This is in reference to our earlier intimation dated 04<sup>th</sup> August, 2025, pursuant to Regulation 30 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), regarding holding of Board Meeting on 12<sup>th</sup> August, 2025 to *inter alia* approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30<sup>th</sup> June, 2025.

The Board of Directors at its meeting held today, i.e. 12<sup>th</sup> August, 2025 has approved the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30<sup>th</sup> June, 2025. A copy of the said Financial Results and Limited Review Report of the Statutory Auditors of the Company, as required under Regulation 33 of the SEBI LODR Regulations, is enclosed herewith.

The meeting of the Board of Directors of the Company commenced at 11.00 a.m. and concluded at 01.25 p.m.

The above information is also available on the website of the Company at [www.alkemlabs.com](http://www.alkemlabs.com)

Kindly take the same on record.

Sincerely,  
For Alkem Laboratories Limited



**Manish Narang**  
**President - Legal, Company Secretary & Compliance Officer**

Encl.: a/a

## **INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS**

### **TO THE BOARD OF DIRECTORS OF Alkem Laboratories Limited**

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Alkem Laboratories Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and its share of the net loss after tax and total comprehensive income of its associate for the quarter ended June 30, 2025 ("the Statement") which includes one branch of the Group located at Nepal being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure 1 to this report.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**Deloitte  
Haskins & Sells LLP**

6. We did not review the interim financial information / financial results of five subsidiaries included in the consolidated unaudited financial results, whose interim financial information/ financial results reflect total revenues of Rs. 3,548.2 million for the quarter ended June 30, 2025, total net profit after tax of Rs. 145.5 million for the quarter ended June 30, 2025 and total comprehensive income of Rs. 156.1 million for the quarter ended June 30, 2025, as considered in the Statement. These interim financial information / financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of this matter.

7. The consolidated unaudited financial results includes the interim financial information/ financial results of twenty one subsidiaries which have not been reviewed by their auditors, whose financial information/ financial results reflect total revenue of Rs. 2,156.9 million for the quarter ended June 30, 2025, total net profit after tax of Rs. 68.9 million for the quarter ended June 30, 2025 and total comprehensive income of Rs. 114.2 million for the quarter ended June 30, 2025, as considered in the Statement. The consolidated unaudited financial results also includes the Group's share of loss after tax of Rs. (4.1 million) for the quarter ended June 30, 2025 and total comprehensive income of Rs. (4.1 million) for the quarter ended June 30, 2025, as considered in the Statement, in respect of one associate, based on their interim financial information which have not been reviewed by their auditor. According to the information and explanations given to us by the Management, these interim financial information / financial results are not material to the Group.

Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial information / results certified by the Management.

8. The comparative financial information of the Group for the quarter ended June 30, 2024 prepared in accordance with Ind AS included in this Statement have been reviewed, by the predecessor auditor. The report of the predecessor auditor on this comparative financial information dated August 09, 2024 expressed an unmodified conclusion.

Our conclusion on the Statement is not modified in respect of this matter.

 For **Deloitte Haskins & Sells LLP**  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)



**Rupen K. Bhatt**  
(Partner)  
(Membership No. 046930)  
(UDIN: **25046930BMODSM8582**)

Place: Mumbai  
Date: August 12, 2025



**ANNEXURE I TO THE INDEPENDENT AUDITOR'S REVIEW REPORT**

(Referred to in paragraph 4 under Independent Auditor's Review Report of even date)

<b>S.N.</b>	<b>Name of the component</b>	<b>Relationship</b>
1	Alkem Laboratories Limited	Parent
2	S&B Holdings S.a.r.l	Wholly Owned Subsidiary
3	The Pharma Network LLC, USA (TPN)	Wholly Owned Subsidiary of S&B Holdings S.a.r.l.
4	Ascend Laboratories LLC, USA	Wholly Owned Subsidiary of TPN
5	S & B Pharma LLC	Wholly Owned Subsidiary of TPN
6	Pharmacor Pty Limited, Australia	Wholly Owned Subsidiary
7	Pharmacor SPA, Chile	Wholly Owned Subsidiary of Pharmacor Pty Limited, Australia
8	Enzene Biosciences Ltd, India	Subsidiary
9	Ascend Laboratories (PTY) Ltd, South Africa	Wholly Owned Subsidiary
10	Cachet Pharmaceuticals Private Limited, India	Subsidiary
11	Indchemie Health Specialties Private Limited, India	Subsidiary
12	Alkem Laboratories Corporation, Philippines	Wholly Owned Subsidiary
13	Ascend GmbH, Germany	Wholly Owned Subsidiary
14	Ascend Laboratories SDN BHD., Malaysia	Wholly Owned Subsidiary
15	Ascend Laboratories SpA Chile (Ascend Chile)	Wholly Owned Subsidiary
16	Pharma Network SpA, Chile	Wholly Owned Subsidiary of Ascend Chile
17	Ascend Laboratories S.A. DE C.V., Mexico	Wholly Owned Subsidiary of Ascend Chile
18	Alkem Laboratories Korea Inc, Korea	Wholly Owned Subsidiary
19	Pharmacor Ltd, Kenya	Wholly Owned Subsidiary
20	The Pharma Network LLP, Kazakhstan	Wholly Owned Subsidiary
21	Ascend Laboratories (UK) Ltd, UK	Wholly Owned Subsidiary
22	Ascend Laboratories Ltd, Canada	Wholly Owned Subsidiary
23	Alkem Foundation, India	Wholly Owned Subsidiary
24	Connect 2 Clinic Private Limited, India	Wholly Owned Subsidiary
25	Ascend Laboratories SAS, Colombia	Wholly Owned Subsidiary
26	Pharmacor Limited, New Zealand	Wholly Owned Subsidiary of Pharmacor Pty Limited, Australia
27	Enzene Inc., USA	Wholly Owned Subsidiary of Enzene Biosciences Ltd, India
28	Alkem Medtech Private Limited, India	Wholly Owned Subsidiary
29	Alixer Nexgen Therapeutics Limited	Wholly Owned Subsidiary
30	Alkem Wellness Limited	Wholly Owned Subsidiary
31	Adroit Biomed Limited	Wholly Owned Subsidiary
32	Bombay Ortho Industries Private Limited	Wholly Owned Subsidiary of Alkem Medtech Private Limited, India
33	Haystack Analytics Private Limited	Associate

Q

# ALKEM LABORATORIES LIMITED

CIN No.:L00305MH1973PLC174201

Regd. Office and Corporate Office: Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai - 400013, Maharashtra, India.

Tel No:91 22 3982 9999 Fax No: +91 22 2492 7190

Website : www.alkemlabs.com, Email Id : investors@alkem.com

## Statement of Consolidated Financial Results for the Quarter ended 30 June 2025

(₹ in Million except per share data)

	Particulars	Quarter ended			Year ended
		30.06.2025 Unaudited (Refer Note 2)	31.03.2025 Unaudited (Refer Note 3)	30.06.2024 Unaudited (Refer Note 4)	31.03.2025 Audited
<b>1</b>	<b>Income</b>				
	(a) Revenue from Operations	33,711.4	31,437.5	30,318.2	129,645.2
	(b) Other Income	1,364.9	1,459.6	1,203.1	4,937.4
	<b>Total Income</b>	<b>35,076.3</b>	<b>32,897.1</b>	<b>31,521.3</b>	<b>134,582.6</b>
<b>2</b>	<b>Expenses</b>				
	(a) Cost of materials consumed	8,271.1	7,770.3	8,371.6	34,403.7
	(b) Purchases of stock-in-trade	3,972.0	3,799.6	3,826.6	15,140.2
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(531.5)	1,222.9	(1,438.7)	(1,901.3)
	(d) Employee benefits expense	6,932.5	6,163.5	6,022.7	24,539.2
	(e) Finance costs	297.8	284.2	291.1	1,217.0
	(f) Depreciation and amortisation expense	876.8	1,124.9	804.8	3,571.6
	(g) Other expenses	7,676.8	8,568.3	7,449.6	32,341.9
	<b>Total Expenses</b>	<b>27,495.5</b>	<b>28,933.7</b>	<b>25,327.7</b>	<b>109,312.3</b>
<b>3</b>	<b>Profit before exceptional items and tax (1) - (2)</b>	<b>7,580.8</b>	<b>3,963.4</b>	<b>6,193.6</b>	<b>25,270.3</b>
<b>4</b>	<b>Exceptional items (refer note 6)</b>	<b>129.3</b>	-	-	-
<b>5</b>	<b>Profit before tax (3) + (4)</b>	<b>7,710.1</b>	<b>3,963.4</b>	<b>6,193.6</b>	<b>25,270.3</b>
<b>6</b>	<b>Tax expense / (credit)</b>				
	(a) Current tax	1,411.1	842.5	1,244.3	5,236.0
	(b) Deferred tax	(384.2)	(109.2)	(553.1)	(2,125.7)
	<b>Total Tax Expense (a + b)</b>	<b>1,026.9</b>	<b>733.3</b>	<b>691.2</b>	<b>3,110.3</b>
<b>7</b>	<b>Share in loss after tax of associate</b>	<b>(4.1)</b>	<b>(6.2)</b>	-	<b>(6.2)</b>
<b>8</b>	<b>Profit for the period (5) - (6) + (7)</b>	<b>6,679.1</b>	<b>3,223.9</b>	<b>5,502.4</b>	<b>22,153.8</b>
<b>9</b>	<b>Other Comprehensive Income (net of tax)</b>				
	(a) (i) Items that will not be reclassified to profit or loss	(47.6)	(64.3)	(49.8)	(218.1)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	2.9	21.7	16.0	72.1
	(b) (i) Items that will be reclassified to profit or loss	65.5	16.7	74.9	343.2
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	<b>Total Other Comprehensive Income (net of tax)</b>	<b>20.8</b>	<b>(25.9)</b>	<b>41.1</b>	<b>197.2</b>
<b>10</b>	<b>Total Comprehensive Income for the period (8) + (9)</b>	<b>6,699.9</b>	<b>3,198.0</b>	<b>5,543.5</b>	<b>22,351.0</b>
<b>11</b>	<b>Profit attributable to</b>				
	a) Owners of the Company	6,642.6	3,058.6	5,451.6	21,654.8
	b) Non-Controlling Interest	36.5	165.3	50.8	499.0
<b>12</b>	<b>Other Comprehensive Income attributable to</b>				
	a) Owners of the Company	23.1	(25.8)	44.1	207.5
	b) Non-Controlling Interest	(2.3)	(0.1)	(3.0)	(10.3)
<b>13</b>	<b>Total Comprehensive Income attributable to</b>				
	a) Owners of the Company	6,665.7	3,032.8	5,495.7	21,862.3
	b) Non-Controlling Interest	34.2	165.2	47.8	488.7
<b>14</b>	<b>Paid-up Equity Share Capital</b> (Face Value ₹ 2 each fully paid up)	<b>239.1</b>	<b>239.1</b>	<b>239.1</b>	<b>239.1</b>
<b>15</b>	<b>Other Equity</b>				<b>119,609.6</b>
<b>16</b>	<b>Earnings Per Share (not annualised for the quarters) (face value of ₹ 2/- each)</b>				
	(a) Basic (₹)	55.56	25.57	45.60	181.11
	(b) Diluted (₹)	55.56	25.57	45.60	181.11

**Notes to the Consolidated Financial results:**

- 1 The above consolidated financial results are prepared in accordance with the Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- 2 The above consolidated financial results of the Group were reviewed and recommended by the Audit Committee on 11 August 2025 and subsequently approved by the Board of Directors at its meeting held on 12 August 2025. The auditors have issued an unmodified review report on the financial results for the quarter ended 30 June 2025.
- 3 The figures for the quarter ended 31 March 2025 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures upto nine months of the relevant financial year.
- 4 The comparative financial results of the Group for the quarter ended 30 June 2024, prepared in accordance with Ind AS included in this statement have been reviewed by the predecessor auditor. The report of the predecessor auditor on the comparative financial results is dated 9 August 2024.
- 5 The Group has made the following acquisitions in wholly owned subsidiaries during the quarter ended 30 June 2025:
  - (a) 100% stake in Adroit Biomed Limited, on 23 April 2025 for a total consideration of ₹1,400 Million subject to conditions in the agreement.
  - (b) 100% stake in Bombay Ortho Industries Private Limited, on 16 April 2025 through its wholly owned subsidiary Alkem Medtech Private Limited for a total consideration of ₹1,470 Million subject to conditions in the agreement.The said acquisitions do not have any material impact on the results for the quarter ended 30 June 2025.
- 6 Exceptional items for the quarter ended 30 June 2025 primarily includes:
  - (a) Gain of ₹ 142.9 million from the sale of Indore facility classified as held for sale in the previous year and sold in the current period in accordance with the business transfer agreement entered with the buyer.
- 7 The Group operates in one reportable business segment i.e. "Pharmaceuticals", accordingly no separate disclosure of segment information has been made.

By Order of the Board  
For Alkem Laboratories Limited



**B.N. Singh**  
**Executive Chairman**  
DIN: 00760310

Place: Mumbai  
Date: 12 August 2025

## **INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS**

### **TO THE BOARD OF DIRECTORS OF Alkem Laboratories Limited**

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **Alkem Laboratories Limited** ("the Company"), which includes a branch located at Nepal for the quarter ended June 30, 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.





**Deloitte  
Haskins & Sells LLP**

5. The comparative financial information of the Company for the quarter ended June 30, 2024 prepared in accordance with Ind AS included in this Statement have been reviewed by the predecessor auditor. The report of the predecessor auditor on these comparative financial information dated August 09, 2024, expressed an unmodified conclusion. These previously issued financial information have been adjusted to comply with Ind AS 105 "Non-current Assets Held for Sale and Discontinued Operations" and included in this Statement as comparative financial information. The adjustments made to the previously issued financial information to comply with Ind AS have been reviewed by us, as applicable.

Our conclusion on the Statement is not modified in respect of this matter.



For **Deloitte Haskins & Sells LLP**  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)



**Rupen K. Bhatt**  
(Partner)  
(Membership No. 046930)  
(UDIN: 25046930BMODSL5250)

Place: Mumbai  
Date: August 12, 2025



**ALKEM LABORATORIES LIMITED**

CIN No.:L00305MH1973PLC174201

Regd. Office and Corporate Office: Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai - 400013, Maharashtra, India.

Tel No:91 22 3982 9999 Fax No: +91 22 2492 7190

Website : www.alkemlabs.com, Email Id : investors@alkem.com

**Statement of Standalone Financial Results for the Quarter ended 30 June 2025**

(₹ in Million except per share data)

	Particulars	Quarter ended			Year ended
		30.06.2025 (Unaudited) (Refer Note 2)	31.03.2025 (Unaudited) (Refer Note 3)	30.06.2024 (Unaudited) (Refer Note 5)	31.03.2025 (Audited)
<b>1</b>	<b>Continuing Operations</b>				
	<b>Income</b>				
	(a) Revenue from Operations	23,721.7	20,449.4	21,269.6	88,134.4
	(b) Other Income	1,165.8	1,115.9	1,061.0	5,070.6
	<b>Total Income</b>	<b>24,887.5</b>	<b>21,565.3</b>	<b>22,330.6</b>	<b>93,205.0</b>
<b>2</b>	<b>Expenses</b>				
	(a) Cost of materials consumed	6,153.3	4,514.1	6,079.7	23,959.2
	(b) Purchases of stock-in-trade	835.1	852.4	783.6	3,896.1
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	79.3	1,871.4	(418.6)	566.1
	(d) Employee benefits expense	4,697.4	4,016.3	4,007.0	16,309.6
	(e) Finance costs	127.9	169.1	210.2	761.1
	(f) Depreciation and amortisation expenses	588.9	916.4	630.6	2,836.1
	(g) Other expenses	5,751.8	6,227.3	5,205.2	21,841.4
	<b>Total Expenses</b>	<b>18,233.7</b>	<b>18,567.0</b>	<b>16,497.7</b>	<b>70,169.6</b>
<b>3</b>	<b>Profit before exceptional items and tax from continuing operations (1) - (2)</b>	<b>6,653.8</b>	<b>2,998.3</b>	<b>5,832.9</b>	<b>23,035.4</b>
<b>4</b>	<b>Exceptional items (Refer note 6)</b>	<b>142.9</b>	-	-	-
<b>5</b>	<b>Profit before tax from continuing operations (3) + (4)</b>	<b>6,796.7</b>	<b>2,998.3</b>	<b>5,832.9</b>	<b>23,035.4</b>
<b>6</b>	<b>Tax expense / (credit)</b>				
	(a) Current tax	1,093.4	367.5	911.2	3,501.3
	(b) Deferred tax	(519.3)	372.0	(535.7)	(1,363.1)
	<b>Total Tax expense (a + b)</b>	<b>574.1</b>	<b>739.5</b>	<b>375.5</b>	<b>2,138.2</b>
<b>7</b>	<b>Profit for the period after tax from continuing operations (5 - 6)</b>	<b>6,222.6</b>	<b>2,258.8</b>	<b>5,457.4</b>	<b>20,897.2</b>
	<b>Discontinued operations (Refer note 4)</b>				
	Profit before tax from discontinued operations	521.0	784.8	576.5	2,938.5
	Tax expense of discontinued operations	182.0	274.2	201.4	1,026.8
<b>8</b>	<b>Profit from discontinued operations (after tax)</b>	<b>339.0</b>	<b>510.6</b>	<b>375.1</b>	<b>1,911.7</b>
<b>9</b>	<b>Profit for the period (7) + (8)</b>	<b>6,561.6</b>	<b>2,769.4</b>	<b>5,832.5</b>	<b>22,808.9</b>
<b>10</b>	<b>Other Comprehensive Income (net of tax)</b>				
	<b>I. In respect of continuing operations:</b>				
	(a) (i) Items that will not be reclassified to profit or loss	(31.4)	(50.8)	(36.6)	(170.3)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	11.0	17.7	12.8	59.5
	(b) (i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	<b>II. In respect of discontinued operations:</b>				
	(a) (i) Items that will not be reclassified to profit or loss	(1.7)	(11.2)	(1.6)	(6.5)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.6	4.0	0.6	2.3
	(b) (i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	<b>Total Other Comprehensive Income (net of tax)</b>	<b>(21.5)</b>	<b>(40.3)</b>	<b>(24.8)</b>	<b>(115.0)</b>
<b>11</b>	<b>Total Comprehensive Income for the period (9) + (10)</b>	<b>6,540.1</b>	<b>2,729.1</b>	<b>5,807.7</b>	<b>22,693.9</b>
<b>12</b>	<b>Paid-up Equity Share Capital</b>	<b>239.1</b>	<b>239.1</b>	<b>239.1</b>	<b>239.1</b>
<b>13</b>	<b>Other Equity</b>				<b>122,979.2</b>
<b>14</b>	<b>Earnings Per Share (not annualised for the quarters) (for continuing operations) (face value of ₹ 2/- each)</b>				
	(a) Basic (₹)	52.04	18.89	45.64	174.78
	(b) Diluted (₹)	52.04	18.89	45.64	174.78
	<b>Earnings Per Share (not annualised for the quarters) (for discontinued operations) (face value of ₹ 2/- each)</b>				
	(a) Basic (₹)	2.84	4.28	3.14	15.99
	(b) Diluted (₹)	2.84	4.28	3.14	15.99
	<b>Earnings Per Share (not annualised for the quarters) (from total operations) (face value of ₹ 2/- each)</b>				
	(a) Basic (₹)	54.88	23.17	48.78	190.77
	(b) Diluted (₹)	54.88	23.17	48.78	190.77

**Notes to the Standalone Financial results:**

- 1 The above standalone financial results are prepared in accordance with the Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- 2 The above standalone financial results of the Company were reviewed and recommended by the Audit Committee on 11 August 2025 and subsequently approved by the Board of Directors at its meeting held on 12 August 2025. The auditors have issued an unmodified review report on the financial results for the quarter ended 30 June 2025.
- 3 The figures for the quarter ended 31 March 2025 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures upto nine months of the relevant financial year.
- 4 The Board of Directors of the Company at their meeting held on 10 December 2024 have approved the transfer of Generic Business Undertaking to Alkem Wellness Limited, a wholly owned subsidiary of the Company as a going concern, on a slump sale basis.

Consequently the proposed transfer of the Generic Business has been disclosed as discontinued operations in accordance with Ind AS 105 "Non - current Assets Held for Sale and Discontinued Operations". The figures for the previous period have been restated to give effect to the presentation requirement of Ind AS 105 "Non - current Assets Held for Sale and Discontinued Operations".

The Company is currently in process of executing the Business Transfer Agreement (BTA) which is expected to be completed on 01 October 2025.

**Key financial information of Discontinued Operations:**


Particulars	(₹ in Million)			
	Quarter ended			Year ended
	30.06.2025	31.03.2025	30.06.2024	31.03.2025
Total income	3,558.2	5,190.5	3,731.4	18,974.9
Total expenses	3,037.2	4,405.7	3,154.9	16,036.4
Profit before tax	521.0	784.8	576.5	2,938.5
Total tax expense	182.0	274.2	201.4	1,026.8
Net profit for the period	339.0	510.6	375.1	1,911.7

- 5 The comparative financial information of the Company for the quarter ended 30 June 2024, prepared in accordance with Ind AS included in this statement have been reviewed by the predecessor auditor. The report of the predecessor auditor on the comparative financial information is dated 09 August 2024. These previously issued financial information have been adjusted to comply with Ind AS 105 "Non-current Assets Held for Sale and Discontinued Operations" and included in this Statement as comparative financial information. The adjustments made to the previously issued financial information to comply with Ind AS have been reviewed by existing auditors, as applicable.
- 6 During the previous year, the Company as part of its ongoing initiative of networking, strategy and optimisation of manufacturing facilities had identified divestment of its Indore facility. The said facility has been sold in the current quarter in accordance with the business transfer agreement entered with the buyer. The resulting gain amounting to ₹ 142.9 million has been classified and disclosed as an Exceptional Item in the results for the quarter ended June 30, 2025.
- 7 The Company has made the following acquisitions in wholly owned subsidiaries during the quarter ended 30 June 2025:
  - (a) 100% stake in Adroit Biomed Limited, on 23 April 2025 for a total consideration of ₹1,400 Million subject to conditions in the agreement.
  - (b) 100% stake in Bombay Ortho Industries Private Limited, on 16 April 2025 through its wholly owned subsidiary Alkem Medtech Private Limited for a total consideration of ₹1,470 Million subject to conditions in the agreement.

The said acquisitions do not have any material impact on the results for the quarter ended 30 June 2025.

- 8 The Company operates in one reportable business segment i.e. "Pharmaceuticals", accordingly no separate disclosure of segment information has been made.

By Order of the Board  
For Alkem Laboratories Limited



**B.N. Singh**  
Executive Chairman  
DIN: 00760310

Place: Mumbai  
Date: 12 August 2025

## Press Release

# Alkem reports 11% revenue growth, 22% rise in net profit in Q1 FY26.

**Mumbai, August 12, 2025:** Alkem Laboratories Ltd. today announced its standalone and consolidated financial results for the first quarter ended June 30, 2025. The Board of Directors took record of these results at its meeting held in Mumbai today.

## Key Financial Metrics



## Key highlights of Q1 FY26 financial performance

- Total Revenue from Operations was ₹33,711 million, with YoY growth of 11.2%.
  - India sales were ₹22,650 million, YoY growth of 12.0%.
  - International sales were ₹10,539 million, with YoY growth of 8.9%.
- Earnings before Interest, Tax, Depreciation, and Amortisation (EBITDA) were ₹7,391 million, resulting in an EBITDA margin of 21.9% vs. 20.1% in Q1 FY25. EBITDA grew by 21.4% YoY.
- R&D expenses for Q1 FY26 were ₹1,184 million, or 3.5% of total revenue from operations, vs. ₹1,257 million in Q1 FY25 at 4.1% of total revenue from operations.
- Profit before tax before exceptional items was ₹7,581 million, YoY growth of 22.4%.
- Net Profit (after Minority Interest) was ₹6,643 million, YoY growth of 21.8%.
- According to IQVIA (SSA) data, for Q1 FY26:
  - The Company registered a growth of 9.7% YoY compared to the Indian Pharmaceutical Market (IPM), which grew by 8.5%.
  - We achieved strong overall volume growth of 2.9%, outperforming the IPM volume growth of 1.5% by 140 basis points.

*Commenting on the Q1 FY26 results, Dr. Vikas Gupta, CEO of Alkem, said, “Q1 FY26 marked a strong start to the year, with healthy growth across both our domestic and international markets. Our performance was driven by strong topline growth and an improved gross margin, which resulted in a better EBITDA profile. These results reflect the disciplined execution of our strategy, focused investments, and a deliberate pivot toward value-accretive products and markets with a sharper focus on EBITDA. We are strategically accelerating our focus on the non-US business segment by strengthening our presence in high-potential non-US markets and capturing new opportunities that align with our long-term growth ambitions.”*



## Operational Highlights

### Domestic Business – Q1 FY26 Key Highlights

- India sales were ₹22,650 million, YoY growth of 12.0%.
- The contribution of domestic sales to total sales in Q1 FY26 was 68.3% vs. 67.6% in Q1 FY25.
- As per IQVIA (SSA) data, during the quarter, we have outperformed IPM in seven therapies: Gastrointestinal grew by ~1.6X, VMN ~2.3X, Pain ~1.4X, Anti-Diabetics ~1.4X, Neuro/CNS ~1.2X, Respiratory ~1.4X, and Derma ~1.1X.

### International Business – Q1 FY26 Key Highlights

- International sales were ₹10,539 million, YoY growth of 8.9%.
- US sales were ₹6,982 million, YoY growth of 8.8%.
- US business sales contributed 21.0% to total sales in Q1 FY26.
- Non-US sales were ₹3,556 million, YoY growth of 9.1%.
- Non-US business sales contributed 10.7% to total sales in Q1 FY26.
- During the Q1 FY26, for the US market, the Company filed its first BLA, received 05 ANDA approvals (including 02 tentative approvals) and launched 03 products.
- As of June 30, 2025, the Company had filed 185 ANDAs, 02 NDAs and 01 BLA with the USFDA. It has received approvals for 160 ANDAs (including 15 tentative approvals) and 02 NDAs.

**About Alkem:** Alkem Laboratories Ltd. is the fifth-largest pharmaceutical company in the Indian market, with a legacy spanning over 50 years of providing high-quality medicines to patients. It holds a dominant position in the therapy areas of anti-infectives, gastrointestinal disorders, pain management, and supplements. It also has a growing portfolio of products in chronic therapies, including diabetes, neurology, dermatology, and urology. It has 18 state-of-the-art manufacturing facilities and cutting-edge research and development (R&D) centres to develop and manufacture generic formulations, active pharmaceutical ingredients (APIs) and biosimilars. Apart from India, the company has a meaningful presence in the US, Latin America, Australia, and several other Asian countries. “Inspiring Healthier Lives” is at the core of the organisation's values and culture, reinforcing its steadfast commitment to improving global health. For more information, please visit [www.alkemlabs.com](http://www.alkemlabs.com) and follow us on [LinkedIn](#), [Instagram](#), and [Facebook](#).

### Contact

#### Investors:

Purvi Shah – Head of Investor Relations  
+91 84337 00890  
[purvi.shah@alkem.com](mailto:purvi.shah@alkem.com)  
+91-22-3982 9999 Ext: 9447

#### Media:

Isha Trivedi  
+91 98925 90003  
[alkemcorpcomm@alkem.com](mailto:alkemcorpcomm@alkem.com)  
+91-22-3982 9999 Ext: 9672

**Invite for Q1 FY26 Conference Call at 5.00 pm IST, August 12, 2025**

**Mumbai, August 07, 2025:** Alkem Laboratories Ltd. (NSE: ALKEM, BSE: 539523, Bloomberg: ALKEM.IN, Reuters: ALKE.NS) will hold a conference call for investors and analysts on Tuesday, August 12, 2025, from 5:00 pm to 6:00 pm IST to discuss its Q1 FY26 financial results. The call will follow the announcement of the Company's Q1 FY26 financial results on Tuesday, August 12, 2025.

**Alkem Laboratories Ltd. will be represented on the call by:**

Dr. Vikas Gupta – CEO  
Mr. Nitin Agrawal – CFO

**Motilal Oswal Securities Ltd. will host the call.**

**Details of the conference call are as follows:**

**Time:** 5:00 pm IST (GMT + 5:30) on Tuesday, August 12, 2025.

**Dial in Details:**

India: +91 22 6280 1149 / +91 22 7115 8050

**International Toll-Free**

USA	: 1 866 746 2133
UK	: 0 808 101 1573
Singapore	: 800 101 2045
Hong Kong	: 800 964 448

**Express Join with Diamond Pass**

<https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=9357875&linkSecurityString=46351d096d>

You are requested to dial in 10 minutes ahead of the

**Purvi Shah / Isha Trivedi**

Investor Relations / Media  
Alkem Laboratories Ltd.

Mobile: +91 84337 00890 / 98925 90003

Tel.: +91 22 3982 9999 Ext: 9447

E-mail: [purvi.shah@alkem.com](mailto:purvi.shah@alkem.com)/  
[isha.trivedi@alkem.com](mailto:isha.trivedi@alkem.com)

**Tushar Manudhane**

Institutional Research Analyst - Healthcare  
Motilal Oswal Securities Ltd.

Tel.: +91 22 6129 1536 / +91 82911 38039

E-mail:

[Tushar.Manudhane@motilaloswal.com](mailto:Tushar.Manudhane@motilaloswal.com)

# Alkem Laboratories Ltd.

## Q1 FY26 Results Presentation

**12<sup>th</sup> August 2025**





# Safe Harbor Statement



This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical fact, including, but not limited to, those that are identified by the use of words such as “anticipates”, “believes”, “estimates”, “expects”, “intends”, “plans”, “predicts”, “projects” and similar expressions. Risks and uncertainties that could affect us include, without limitation:

- General economic and business conditions in India and other key global markets in which we operate;
- The ability to successfully implement our strategy, our research and development efforts, growth & expansion plans and technological changes;
- Changes in the value of the Rupee and other currency changes;
- Changes in the Indian and international interest rates;
- Allocations of funds by the Governments in our key global markets;
- Changes in laws and regulations that apply to our customers, suppliers, and the pharmaceutical industry;
- Increasing competition in and the conditions of our customers, suppliers and the pharmaceutical industry; and
- Changes in political conditions in India and in our key global markets.

Should one or more of such risks and uncertainties materialize, or should any underlying assumption prove incorrect, actual outcomes may vary materially from those indicated in the applicable forward-looking statements. Any forward-looking statement or information contained in this presentation speaks only as of the date of the statement. We are not required to update any such statement or information to either reflect events or circumstances that occur after the date the statement or information is made or to account for unanticipated events, unless it is required by Law.

# CONTENTS



**Company's Financial Performance**



**Business Updates – Q1 FY26**



**Company overview and journey so far**

## Q1 FY26 Performance at Glance

### Total Revenue from Operations

**₹33,711 Mn**

 **+11.2% YoY Growth**

### EBITDA / Margin

**₹7,391 Mn / 21.9%**

 **+21.4% YoY Growth**

### PAT<sup>1</sup> / Margin

**₹6,643 Mn / 19.7%**

 **+21.8% YoY Growth**

## Geographic-wise Break-Up

**Domestic  
Business**

**68.3%**

**International  
Business**

**31.7%**

## Salient Numbers

**₹48.7 Bn**

Net Cash as of 30<sup>th</sup> June 2025

**₹1,184 Mn**

R&D spend for Q1 FY26

**120 bps**

Outperformance in the domestic  
market vs. IPM

**3.5%**

R&D spend as % of sales during the  
quarter

1. PAT: Profit after Minority Interest



# Q1 FY26 – P&L Highlights

Particulars <i>(All figures in ₹ Mn)</i>	Q1 FY26	Q1 FY25	YoY Growth	Q4 FY25	QoQ Growth
<b>Revenue from Operations</b>	33,711	30,318	11.2%	31,438	7.2%
<b>Gross Profit</b>	22,000	19,559	12.5%	18,645	18.0%
<b>Gross Profit Margin</b>	65.3%	64.5%		59.3%	
<b>EBITDA</b>	7,391	6,086	21.4%	3,913	88.9%
<b>EBITDA Margin</b>	21.9%	20.1%		12.4%	
<b>PBT (before exceptional items)</b>	7,581	6,194	22.4%	3,963	91.3%
<b>Exceptional items<sup>1</sup></b>	129	0		0	
<b>PBT (after exceptional items)</b>	7,710	6,194	24.5%	3,963	94.5%
<b>PAT (after Minority interest)</b>	6,643	5,452	21.8%	3,059	117.3%
<b>PAT Margin</b>	19.7%	18.0%		9.7%	
<b>EPS (₹/share)</b>	55.6	45.6	21.8%	25.6	117.3%

Notes: 1. Exceptional items for the quarter primarily includes gain of ₹142.9 Mn from the sale of the Indore facility

# CONTENTS



**Company's Financial Performance**




**Business Updates – Q1 FY26**



**Company overview and journey so far**

# Domestic Business Performance

**Q1 FY26 sales of ₹22,650 Mn  
(12.0% YoY growth)**




- Domestic business<sup>1</sup> revenue grew by 12.0% YoY to ₹22,650 Mn from ₹20,223 Mn during the same period last year.
- Domestic revenue contributed 68.3% to total sales in Q1 FY26, up from 67.6% in Q1 FY25.
- According to IQVIA (SSA) data, for Q1 FY26:
  - The Company registered a growth of 9.7% YoY compared to the Indian Pharmaceutical Market (IPM), which grew by 8.5%.
  - We've grown faster than the market in seven of IPM's key therapy areas.
  - We achieved strong overall volume growth of 2.9%, outperforming the IPM volume growth of 1.5% by 140 basis points.

1. Includes revenue from Adroit and Bombay Ortho businesses.



# Alkem has delivered a strong performance in Q1 FY26, outpacing the market growth in key focus therapies









***Outpaced the market by 120 bps, delivering 9.7% growth vs. 8.5% for IPM***



■ IPM Sales Growth YoY ■ Alkem Sales Growth YoY


Source: Market data as per IQVIA SSA Qtr. Jun'25

## ***Outperformance in 7 of the key IPM focus therapies***

Therapy Class	Growth YoY %	Market share %	IPM Rank – Value
 Anti Infectives	<div> <div>6.5%</div> <div>6.5%</div> </div>	13.2% ↔	1 ↔
 Gastro Intestinal	<div> <div>6.6%</div> <div>10.5%</div> </div>	7.7% ↑ +0.3%	3 ↔
 VMN	<div> <div>7.8%</div> <div>18.1%</div> </div>	6.4% ↑ +0.6%	2 ↔
 Pain / Analgesics	<div> <div>6.6%</div> <div>9.2%</div> </div>	5.2% ↑ +0.1%	3 ↔
 Anti Diabetic	<div> <div>8.4%</div> <div>12.0%</div> </div>	2.2% ↑ +0.1%	14 ↔
 Neuro / CNS	<div> <div>9.9%</div> <div>11.6%</div> </div>	2.4% ↔	7 ↔
 Respiratory	<div> <div>12.0%</div> <div>16.7%</div> </div>	1.5% ↑ +0.1%	14 ↑ +1
 Derma	<div> <div>5.8%</div> <div>6.0%</div> </div>	1.4% ↔	20 ↔

***15+ years of unmatched leadership in the Anti-Infectives therapy***


## ***Q1 FY26 US Business sales of ₹6,982 Mn (8.8% YoY growth)***



- US business revenue grew by 8.8% YoY to ₹6,982 Mn from ₹6,416 Mn during the same period last year.
- US revenue contributed 21.0% to total sales in Q1 FY26.
- During the Q1 FY26, the Company filed its first BLA, received 05 ANDAs approvals (including 02 tentative approvals) and launched 03 ANDAs.


## US Market Filing and approvals status

### ANDA / BLA Filings



As of June 30, 2025, the Company has **filed 185 ANDAs, 2 NDAs and 1 BLA** and has **received 160 ANDAs approvals** (including 15 tentative approvals) **and 2 NDAs approvals**.


**Q1 FY26 sales of ₹3,556 Mn  
(9.1% YoY growth)**



- Non-US business revenue grew by 9.1% YoY to ₹3,556 Mn from ₹3,261 Mn during the same period last year.
- Non-US revenue contributed 10.7% to total sales in Q1 FY26.
- The Non-US business growth was driven by double-digit growth in Australia and key European markets.



# Shareholding Pattern as on June 30, 2025



■ Promoter & Promoter Group ■ Institution ■ Non-Institution

BSE Ticker	539523
NSE Symbol	ALKEM
Shares Outstanding (Mn)	120
MCap (Rs in Mn)*	590,457
Free Float MCap (Rs in Mn)	277,279
Industry	Pharmaceuticals

*\*Share Price - Rs 4,939 from NSE as of 30th June 2025*

**Institution** – Mutual Funds, Alternate Investment Funds, Foreign Portfolio Investors, Financial Institutions / Banks

**Non-Institution** – Public, Other Bodies Corporates, Clearing Members, Non-Resident Indians, Hindu Undivided Family and Trusts

# CONTENTS



**Company's Financial Performance**



**Business Updates – Q1 FY26**



**Company overview and journey so far**

# Alkem Laboratories at Glance (FY25)



## Market Leadership

**#3**

Rank in  
Prescriptions<sup>1</sup>

**#5**

Rank by value in  
IPM<sup>2</sup>

**Leading Player**

In the Trade  
Generics segment

**Top 3**

Player in 4 out of top  
7 largest IPM's TAs<sup>2</sup>



## Scale

**₹1,29,645 Mn**

Total Revenue<sup>3</sup>

**70.2%**


Domestic Revenue

**18**

Brand families worth  
₹1000 Mn+<sup>2</sup>

**12,500+**

Field force<sup>4</sup>



## Profitability

**63.3%**

Gross Profit  
Margin

**19.4%**

EBITDA Margin

**16.7%**

PAT Margin

**28.1%**

ROCE (Pre-Tax)

1. Prescriptions data as per SMSRC MAT Mar'25; 2. Market data as per IQVIA SSA MAT Mar'25; 3. Including Other Operating Income; 4. Excluding Line Managers as of 31<sup>st</sup> March 2025

Strong momentum from our mega brands has been pivotal in building robust brand franchises and consistently scaling them over the years

## #2 'PAN'

Biggest Brand family in the IPM

## 17 Brands

in the IPM Top 300 ranks

## 35 Brands

Among the Top 3 ranks in their CVM<sup>1</sup> (Brands > ₹250 Mn)

*Building large brand families defines our identity...*

Brand Families	MAT Mar'20	MAT Mar'25	CAGR (5 Yrs.)
> ₹10 Bn	0	1	16.1%
> ₹5 Bn	1	1	7.7%
> ₹1.5 Bn	6	11	10.4%
> ₹500 Mn	11	12	13.2%

Brand family > ₹5 Bn

**PAN** **CLAVAM**

Brand family > ₹1.5 Bn





  



  
**TAXIM** **SUMOL** **CHERi**



# 50+ years of Alkem journey – a snapshot.



## Alkem & key subsidiaries



# THANK YOU

**For any queries, contact:**  
**Purvi Shah**

**Mobile: +91 84337 00890**

**E-mail: [purvi.shah@alkem.com](mailto:purvi.shah@alkem.com)**

**Tel: +91 22 3982 9999 Ext: 9447**

Stay updated on     

Disclaimer: This is a confidential email from Alkem Laboratories Limited. The contents of this email and any attachments are solely intended for the addressee(s) and in all likelihood contain information that is legally privileged. If you are not the intended recipient of this email, you are on notice of its status and we request you to kindly advise us by return email immediately. Please also simultaneously disregard the contents herein, delete this email from your computer and server and also destroy any physical copies, if created. You are hereby notified that any use, any form of reproduction, dissemination, copying, disclosure, modification, distribution and/or publication of this e-mail, its contents or its attachment/s other than by its intended recipient/s is strictly prohibited and may be construed unlawful. Alkem Laboratories Limited does not accept any liability for the views expressed in this email or for the consequences of any viruses that may be transmitted with this email. The content of this email is subject to copyright and no part hereof may be reproduced, adapted or transmitted without the written consent of Alkem Laboratories Limited.